These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 25242390)

  • 1. Dutasteride and enzalutamide synergistically suppress prostate tumor cell proliferation.
    Hamid AR; Verhaegh GW; Smit FP; van Rijt-van de Westerlo C; Armandari I; Brandt A; Sweep FC; Sedelaar JP; Schalken JA
    J Urol; 2015 Mar; 193(3):1023-9. PubMed ID: 25242390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models.
    Ateeq B; Vellaichamy A; Tomlins SA; Wang R; Cao Q; Lonigro RJ; Pienta KJ; Varambally S
    Prostate; 2012 Oct; 72(14):1542-9. PubMed ID: 22415461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors.
    Wu Y; Godoy A; Azzouni F; Wilton JH; Ip C; Mohler JL
    Prostate; 2013 Sep; 73(13):1470-82. PubMed ID: 23813697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5α-reductase type 3 enzyme in benign and malignant prostate.
    Titus MA; Li Y; Kozyreva OG; Maher V; Godoy A; Smith GJ; Mohler JL
    Prostate; 2014 Feb; 74(3):235-49. PubMed ID: 24150795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The direct inhibitory effect of dutasteride or finasteride on androgen receptor activity is cell line specific.
    Chhipa RR; Halim D; Cheng J; Zhang HY; Mohler JL; Ip C; Wu Y
    Prostate; 2013 Oct; 73(14):1483-94. PubMed ID: 23813737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
    Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
    Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of protein kinase C/Twist1 signaling augments anticancer effects of androgen deprivation and enzalutamide in prostate cancer.
    Shiota M; Yokomizo A; Takeuchi A; Imada K; Kashiwagi E; Song Y; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
    Clin Cancer Res; 2014 Feb; 20(4):951-61. PubMed ID: 24352647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines.
    Biancolella M; Valentini A; Minella D; Vecchione L; D'Amico F; Chillemi G; Gravina P; Bueno S; Prosperini G; Desideri A; Federici G; Bernardini S; Novelli G
    Invest New Drugs; 2007 Oct; 25(5):491-7. PubMed ID: 17636412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of RSK/YB-1 signaling enhances the anti-cancer effect of enzalutamide in prostate cancer.
    Shiota M; Yokomizo A; Takeuchi A; Itsumi M; Imada K; Kashiwagi E; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
    Prostate; 2014 Jun; 74(9):959-69. PubMed ID: 24740858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy.
    Li Z; Alyamani M; Li J; Rogacki K; Abazeed M; Upadhyay SK; Balk SP; Taplin ME; Auchus RJ; Sharifi N
    Nature; 2016 May; 533(7604):547-51. PubMed ID: 27225130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
    Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
    Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice.
    Gupta S; Wang Y; Ramos-Garcia R; Shevrin D; Nelson JB; Wang Z
    Prostate; 2010 Oct; 70(14):1575-85. PubMed ID: 20564326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of sorafenib and enzalutamide as a potential new approach for the treatment of castration-resistant prostate cancer.
    Wu H; Zhang L; Gao X; Zhang X; Duan J; You L; Cheng Y; Bian J; Zhu Q; Yang Y
    Cancer Lett; 2017 Jan; 385():108-116. PubMed ID: 27815035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells.
    Gaur S; Gross ME; Liao CP; Qian B; Shih JC
    Prostate; 2019 May; 79(6):667-677. PubMed ID: 30693539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Curcumin Combined With the 5-alpha Reductase Inhibitor Dutasteride on LNCaP Prostate Cancer Cells.
    Nakayama A; Ide H; Lu Y; Takei A; Fukuda K; Osaka A; Arai G; Horie S; Okada H; Saito K
    In Vivo; 2021; 35(3):1443-1450. PubMed ID: 33910821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells.
    Verma K; Gupta N; Zang T; Wangtrakluldee P; Srivastava SK; Penning TM; Trippier PC
    Mol Cancer Ther; 2018 Sep; 17(9):1833-1845. PubMed ID: 29891491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.
    Tindall DJ; Rittmaster RS
    J Urol; 2008 Apr; 179(4):1235-42. PubMed ID: 18280514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of telomerase potentiates enzalutamide efficiency of androgen-sensitive human prostate cancer cells.
    Gecgel KK; Muduroglu M; Erdogan S
    J BUON; 2017; 22(6):1570-1576. PubMed ID: 29332354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-oncogenic effects of dutasteride, a dual 5-alpha reductase inhibitor and a drug for benign prostate hyperplasia, in bladder cancer.
    Seok J; Kwak HJ; Kwak Y; Lee M; Park KS; Kim A; Cho SG
    J Transl Med; 2023 Feb; 21(1):129. PubMed ID: 36800968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dutasteride in the treatment of hormone refractory prostate cancer].
    Arena F
    Minerva Urol Nefrol; 2008 Jun; 60(2):71-6. PubMed ID: 18500220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.